2-Propenoic acid, 3-[4'-[2-(hydroxyamino)-1-methyl-2-oxoethoxy]-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl]-, (2E)- manufacturers
- GEM144
-
- $378.00
-
2026-05-11
- CAS:2487526-28-1
- Purity: 98.10%
- Supply Ability: 10g
|
| | 2-Propenoic acid, 3-[4'-[2-(hydroxyamino)-1-methyl-2-oxoethoxy]-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl]-, (2E)- Basic information |
| | 2-Propenoic acid, 3-[4'-[2-(hydroxyamino)-1-methyl-2-oxoethoxy]-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl]-, (2E)- Chemical Properties |
| density | 1.281±0.06 g/cm3(Predicted) | | pka | 4.49±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | 2-Propenoic acid, 3-[4'-[2-(hydroxyamino)-1-methyl-2-oxoethoxy]-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl]-, (2E)- Usage And Synthesis |
| Uses | GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts[1]. | | in vivo | GEM144 (50 mg/kg; p.o., bid, 5 days a week, for 3-4 weeks) significantly reduces tumor burden of MM487 with TGI of 72% in xenografts mice[1]. | Animal Model: | Female CD-1 nude mice (injected with MM473 and MM487)[1] | | Dosage: | 50 mg/kg | | Administration: | PO, bid, 5 days a week, for 3-4 weeks | | Result: | Significantly reduced tumor burden of MM487 with TGI of 72%. |
| | IC 50 | HDAC11: 8.23 μM (IC50) | | References | [1] Dallavalle S, et al. Antitumor activity of novel POLA1-HDAC11 dual inhibitors. Eur J Med Chem. 2022;228:113971. DOI:10.1016/j.ejmech.2021.113971 |
| | 2-Propenoic acid, 3-[4'-[2-(hydroxyamino)-1-methyl-2-oxoethoxy]-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl]-, (2E)- Preparation Products And Raw materials |
|